William Ragatz
President and CEO

As President and CEO of Sentrimed, Bill Ragatz has significant and broad commercial experience in addition to expertise in building strong organizations and successfully developing and launching pipeline assets. Bill has over 25 years of experience in the pharmaceutical/biotech industry. Most recently, Bill was SVP, Head of Commercial at Viela Bio, where he built and led the global commercial organization and created the vision and strategy for bringing pipeline assets to market. Bill was integral to Viela’s IPO and its successful acquisition by Horizon Therapeutics. Throughout his career, Bill has led numerous product launches spanning a range of therapeutic areas, including oncology, respiratory, and cardiovascular disease. Bill earned his MBA from the Fuqua School of Business at Duke University.

Dr. Gary S. Goldberg, PhD
Founder and Chief Science Officer

Dr. Gary Goldberg is a founder of Sentrimed, as well as Chief Science Officer, in addition to serving as a Professor at Rowan University. With over 35 years of experience, Dr. Goldberg has worked at major institutes around the world to clarify fundamental mechanisms that control cell behavior and develop approaches to understand and combat cancer. Dr. Goldberg is presently working with colleagues at research centers across the U.S. and around the world to develop these compounds into pharmaceutical reagents that can be used to treat cancer, as well as inflammatory diseases such as arthritis. His work has led to the generation of compounds supported by the NIH and other agencies, with IRB and FDA IND approval for clinical trials aimed to prevent and treat cancer. In addition to founding Sentrimed, he founded the international group PDPN Central, which supports translational research and the PBLMed platform to guide medical education.

Dr. Jack Goldberg, MD
Chief Medical Officer

Dr. Jack Goldberg serves as Chief Medical Officer for Sentrimed. With over 40 years of experience in running clinical trials in oncology, particularly in blood cancer, he has deep ties to the oncology community and is the author of over 70 peer-reviewed publications.  Earlier in his career, Dr. Goldberg established the Cooper Cancer Institute in Camden New Jersey in 1988, and the Abramson Comprehensive Cancer Center at Penn Presbyterian in 2002. He also established and has received funding from the NIH for the Community Clinical Oncology Program of New Jersey. Dr. Goldberg is a past Chairperson of the NCI Biology and Immunology Contracts Review Committee. He served as the American Cancer Society Professor of Clinical Oncology from 1992 to 2002. He is certified by the American Board of Internal Medicine, the American Subspecialty Board of Hematology, and the American Subspecialty Board of Oncology. Dr. Goldberg serves on the board of the American Cancer Society Camden County and has been an active member of the Cancer and Acute Leukemia Group B and the Leukemia Intergroup.

Dr. Arye Rosen, PhD
Vice President

Dr. Arye Rosen has published over 200 peer-reviewed papers, several books and book chapters, is an inventor on over 60 U.S. patents, and a member of the National Academy of Engineering, which is part of the National Academies of Sciences and Medicine.  In addition to playing a core role in building several organizations, Dr. Rosen has been engaged in research at Jefferson Medical College in the Division of Cardiology and the Dept of Surgery for many years. He also held a position as Academy Professor of Biomedical and Electrical Engineering in the School of Biomedical Engineering, Science and Health Systems at Drexel University where he served as a Principal Investigator to perform NIH funded research. In 2003, Dr. Rosen co-founded the Medical Technology Center for Infants and Children at St. Peter’s University Hospital in New Brunswick, NJ, in addition to founding AMT Inc, (Advanced Medical Technologies). Previously, Dr. Rosen has engaged in research funded by the Bill and Melinda Gates Foundation and other projects funded by NIH grants including SBIR/STTR grants. More recently, Dr. Rosen has served as Associate VP for Biomedical Research Partnerships at Rowan University, with a passion for mentoring faculty working to develop and commercialize innovative medical technologies. In 2019 Dr. Rosen was appointed to Affiliated Professor in the School of Engineering at Drexel University, and in 2022 Vice President of Sentrimed Inc. Dr. Rosen is eager to utilize his extensive experience to move Sentrimed into clinical trials and beyond.

Sue Slezak
Vice President, New Product Planning

Sue Slezak brings more than 25 years of pharmaceutical/biotech experience to Sentrimed in the areas of new product planning, commercial and life cycle management. Sue brings a passionate commitment to improving treatments and outcomes for patients and payors. Sue has a highly successful track record of launches in a variety of different settings including novel mechanisms, orphan/rare diseases, life cycle management and co-promotion products across a variety of different therapeutic areas during her tenure at Alexion/AstraZeneca, Shire/Takeda, Viela Bio/Horizon and other biotechs. Prior leadership roles in corporate strategy, pipeline development, commercial assessments and investment banking have resulted in multiple mergers, acquisitions, business development deals and investment recommendations across the healthcare sector. Sue earned her MBA from Villanova University, holds a Bachelor’s degree in the Biological Sciences from Rochester Institute of Technology and a master’s education in Immunology from the Medical College of Pennsylvania/Drexel College of Medicine and is an author of numerous scientific publications, book chapters and patents.